Glucagon Market Analysis

Glucagon Market Analysis

Based on product type, the market is divided into injectable and inhalation. The injectable segment is estimated to account for USD 364.7 million by the end of 2032.
 

• Injectable glucagon has a rapid onset of action, typically within minutes of administration. This rapid response is crucial in emergency situations where immediate correction of hypoglycemia is required to prevent serious complications.
   
• It is available in compact, portable kits that can be easily carried in a purse, pocket, or first aid kit. This portability ensures that glucagon is readily accessible in case of emergency, whether at home, work, or while traveling.
   
• Further, injectable glucagon is simple to administer, making it suitable for use by patients, caregivers, and healthcare professionals alike. The administration process typically involves reconstituting the powdered glucagon with a diluent and then injecting it subcutaneously, intramuscularly, or intravenously. Thus, stimulating the growth of the segment.
   

Alt tag : Glucagon Market, By Application (2023)

Based on application, the glucagon market is bifurcated into hypoglycemia, diagnostic aid, gastrointestinal disorders, cardiogenic shock, and other applications. The hypoglycemia segment accounted for USD 145.1 million in 2023.

• Glucagon acts quickly to raise blood sugar levels, making it essential in situations wherein hypoglycemia is severe or in the condition where person is unconscious and unable to consume sugar orally.
• By raising blood sugar levels, glucagon helps counteract the symptoms of hypoglycemia includes confusion, dizziness, sweating, and in severe cases, loss of consciousness or seizures.
• Further, glucagon is often used as an emergency treatment for severe hypoglycemia, especially in individuals affected by diabetes and prone to experiencing episodes of dangerously low blood sugar level. Thus, such aforementioned factors are expected to augment the segmental growth.

Based on distribution channel, the glucagon market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is estimated to account for USD 334.3 million revenue by the end of 2032.

• Hospital pharmacists are highly trained professionals with expertise in medication management including storage, handling, and administration of medications such as glucagon.
• They stock glucagon, ensuring its readiness for emergency use. This quick access is crucial in situations requiring immediate treatment to raise blood sugar levels in patients experiencing severe hypoglycemia.
• Further, hospital pharmacies can prepare customized dosages or formulations of glucagon as per the specific needs of patients such as adjusting concentrations for pediatric use or preparing alternative formulations for patients with allergies or sensitivities.

U.S. glucagon market is anticipated to grow at CAGR of 5.7% during the analysis timeframe.
 

• The U.S. has a highly developed pharmaceutical industry with advanced manufacturing capabilities. This allows for the production of high-quality glucagon products meeting stringent regulatory standards.
   

• It has a significant prevalence of diabetes. For instance, The National Diabetes Statistics Report for 2022 by the Centers for Disease Control (CDC) reveals that the prevalence of diabetes has increased, reached an estimated 37.3 million cases. This accounted for 11.3% of the U.S. population. Among these cases, 28.7 million people received a diabetes diagnosis, while approximately 8.6 million individuals have diabetes but remain undiagnosed.
   

Canada is expected to experience significant expansion within the global market.
 

• Health Canada, the regulatory authority for pharmaceuticals, ensures the safety, efficacy, and quality of medications, including glucagon. This regulatory oversight provides assurance to healthcare providers and patients regarding the reliability of glucagon therapy.
   
• The rising incidence of diabetes contributes significantly to the market's notable expansion. For instance, according to Public Health Agency of Canada, Canada.ca, in 2021, approximately 9.4% of the population, equivalent to 3.7 million individuals were diagnosed with diabetes, with 10% prevalence in males and 8.7% in female.
   

The glucagon market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany boasts a sophisticated healthcare system renowned for its quality and accessibility. This system ensures that medications such as glucagon are readily available to individuals with diabetes or other conditions requiring treatment for hypoglycemia.
   
• The country is at the forefront of technological innovation in healthcare. This innovation may lead to the development of advanced formulations and delivery methods for glucagon, enhancing its efficacy and ease of use.
   

UK is anticipated to witness robust growth in the global glucagon market.
 

• The UK Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of pharmaceutical products. This ensures that glucagon products marketed in the UK meet high standards of safety, quality, and efficacy.
   
• The UK faces a notable burden of diabetes. For instance, data from The British Diabetic Association revealed that more than 4.3 million people in the UK were managing with diabetes, while 850,000 people have diabetes but remain to undiagnosed in 2021.
   

Japan glucagon market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan is known for its technological innovation in healthcare including pharmaceuticals. This innovation can lead to the development of advanced formulations and delivery methods for glucagon, improving its effectiveness and ease of use.
•  
• The country has a significant prevalence of diabetes. For instance, according to International Diabetes Federation, in 2021, Japan experienced a diabetes prevalence of 11.8% among its total population, equating to approximately 11,004,999 cases in adults.
   

The glucagon market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia provides universal healthcare coverage to its citizens and residents through the Ministry of Health (MOH) and other government agencies. This ensures equitable access to medications such as glucagon for individuals with diabetes or other medical conditions.
   
• The increasing prevalence of diabetes is evident in Saudi Arabia. For instance, according to the International Diabetes Federation, in 2021 the prevalence of diabetes among adults in the country reached 17.7%, totaling approximately 4,274,100 diagnosed cases.